Piper Sandler raised the firm’s price target on Masimo to $150 from $135 and keeps a Neutral rating on the shares post the Q4 results. The analyst says the stock’s valuation "already looks more than full" relative to medtech peers with similar growth profiles.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MASI:
